https://stanfordhealthcare.org/publications/870/870811.html
870811 | Stanford Health Care
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2
stanfordhealthcare